Breaking Finance News

Zacks Investment Research upgraded RedHill Biopharma Ltd – ADR (NASDAQ:RDHL) to Hold in a report released today.

Zacks Investment Research has upgraded RedHill Biopharma Ltd – ADR (NASDAQ:RDHL) to Hold in a report released on 9/28/2016.

Only yesterday RedHill Biopharma Ltd – ADR (NASDAQ:RDHL) traded -1.49% lower at $14.69. RedHill Biopharma Ltd – ADR’s 50-day moving average is $14.94 and its 200-day moving average is $12.70. With the last stock price close up 9.41% from the 200-day average, compared with the S&P 500 Index which has decreased -0.01% over the same time period. 76,305 shares of RDHL traded hands, up from an average trading volume of 36,398

Recent Performance Chart

RedHill Biopharma Ltd - ADR (NASDAQ:RDHL)

RedHill Biopharma Ltd – ADR has 52 week low of $8.10 and a 52 week high of $16.54 and has a market capitalization of $0.

General Company Details For RedHill Biopharma Ltd – ADR (NASDAQ:RDHL)

RedHill Biopharma Ltd. is a biopharmaceutical company focused on the development and acquisition of late clinical-stage, orally administered drugs for the treatment of inflammatory and gastrointestinal diseases, and cancer. The Company's products pipeline includes RHB-105, RHB-104, BEKINDA, RHB-106, YELIVA (ABC294640), MESUPRON, RP101, RIZAPORT and RHB-101. RHB-105 is a fixed-dose oral combination therapy. RHB-104 is an antibiotic combination therapy in oral capsule formulation. BEKINDA is an oral, extended-release (approximately 24 hours), once-daily pill formulation of the antiemetic drug ondansetron. RHB-106 is an encapsulated oral bowel preparation. YELIVA (ABC294640) is a Phase II-stage sphingosine kinase-2 (SK2) selective inhibitor. MESUPRON is a urokinase-type plasminogen activator (uPA) inhibitor. RP101 is a heat shock protein 27 (Hsp27) inhibitor. RIZAPORT is an oral fast dissolving thin film formulation. RHB-101 is a once daily controlled release formulation of Carvedilol.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *